These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Controlled, open, randomized multicenter trial comparing the effects of treatment on quality of life, safety and efficacy of budesonide foam and betamethasone enemas in patients with active distal ulcerative colitis. Hammond A; Andus T; Gierend M; Ecker KW; Scholmerich J; Herfarth H; Hepatogastroenterology; 2004; 51(59):1345-9. PubMed ID: 15362749 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and retrograde colonic spread of budesonide enemas in patients with distal ulcerative colitis. Nyman-Pantelidis M; Nilsson A; Wagner ZG; Borgå O Aliment Pharmacol Ther; 1994 Dec; 8(6):617-22. PubMed ID: 7696451 [TBL] [Abstract][Full Text] [Related]
11. [Budesonide foam as a new therapeutic principle in distal ulcerative colitis in comparison with mesalazine enema. An open, controlled, randomized and prospective multicenter pilot study]. Rufle W; Frühmorgen P; Huber W; Kimmig JM Z Gastroenterol; 2000 Apr; 38(4):287-93. PubMed ID: 10820860 [TBL] [Abstract][Full Text] [Related]
12. Colonic spread of three rectally administered mesalazine (Pentasa) dosage forms in healthy volunteers as assessed by gamma scintigraphy. Brown J; Haines S; Wilding IR Aliment Pharmacol Ther; 1997 Aug; 11(4):685-91. PubMed ID: 9305476 [TBL] [Abstract][Full Text] [Related]
13. Spread and distribution of 5-ASA colonic foam and 5-ASA enema in patients with ulcerative colitis. Campieri M; Corbelli C; Gionchetti P; Brignola C; Belluzzi A; Di Febo G; Zagni P; Brunetti G; Miglioli M; Barbara L Dig Dis Sci; 1992 Dec; 37(12):1890-7. PubMed ID: 1473437 [TBL] [Abstract][Full Text] [Related]
14. Mesalazine foam (Salofalk foam) in the treatment of active distal ulcerative colitis. A comparative trial vs Salofalk enema. The SAF-3 study group. Ardizzone S; Doldo P; Ranzi T; Sturniolo GC; Giglio LA; Annese V; D'Arienzo A; Gaia E; Gullini S; Riegler G; Valentini M; Massa P; Del Piano M; Rossini F; Guidetti CS; Pera A; Greinwald R; Bianchi Porro G Ital J Gastroenterol Hepatol; 1999 Nov; 31(8):677-84. PubMed ID: 10730559 [TBL] [Abstract][Full Text] [Related]
15. Gastrointestinal transit, release and plasma pharmacokinetics of a new oral budesonide formulation. Brunner M; Ziegler S; Di Stefano AF; Dehghanyar P; Kletter K; Tschurlovits M; Villa R; Bozzella R; Celasco G; Moro L; Rusca A; Dudczak R; Müller M Br J Clin Pharmacol; 2006 Jan; 61(1):31-8. PubMed ID: 16390349 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of oral budesonide in the treatment of active distal ulcerative colitis. Kolkman JJ; Möllmann HW; Möllmann AC; Penã AS; Greinwald R; Tauschel HD; Hochhaus G Drugs Today (Barc); 2004 Jul; 40(7):589-601. PubMed ID: 15510233 [TBL] [Abstract][Full Text] [Related]
17. Medical management of ulcerative proctitis, proctosigmoiditis, and left-sided colitis. Bitton A Semin Gastrointest Dis; 2001 Oct; 12(4):263-74. PubMed ID: 11726080 [TBL] [Abstract][Full Text] [Related]
18. Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study. Naganuma M; Aoyama N; Tada T; Kobayashi K; Hirai F; Watanabe K; Watanabe M; Hibi T J Gastroenterol; 2018 Apr; 53(4):494-506. PubMed ID: 28779419 [TBL] [Abstract][Full Text] [Related]
19. [Treating distal ulcerative colitis intrarectally. Foam instead of enema, low volume rather than high volume]. MMW Fortschr Med; 2008 Apr; 150(15):44. PubMed ID: 18510119 [No Abstract] [Full Text] [Related]